MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Johnson & Johnson P/CF Ratio 2011-2026 | JNJ
Annual P/CF Ratio Johnson & Johnson
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 15.6 | 17.7 | 17.9 | 18.9 | - | 19.8 | 18.5 | 19.2 | 17.8 | - | 19.2 | 18.3 | 16.5 | 12 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.8 | 12 | 17.6 |
P/CF Ratio of other stocks in the Biotechnology industry
| Issuer | P/CF Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.654 | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
14.1 | $ 7.68 | - | $ 6.83 B |  Spain |
 |
Altimmune
ALT
|
-4.71 | $ 3.47 | 3.74 % | $ 306 M |  USA |
 |
Amgen
AMGN
|
19.9 | - | - | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
8 | - | - | $ 915 M | USA |
 |
I-Mab
IMAB
|
-0.266 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
11.6 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
1.68 K | - | 2.54 % | $ 160 B |  France |
 |
Heron Therapeutics
HRTX
|
-7.19 | - | - | $ 130 M | USA |
 |
Biophytis SA
BPTS
|
-23.1 | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-17.6 | $ 218.0 | -1.75 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
-13.2 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.88 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.64 | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
-8.36 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-4.82 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-0.0018 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-1.2 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-5 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-1.71 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-2.73 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
-89 | - | - | - |  Russia |
 |
Incyte Corporation
INCY
|
13.8 | $ 90.75 | -0.03 % | $ 17.7 B | USA |
 |
Inovio Pharmaceuticals
INO
|
-1.77 | $ 1.57 | -0.63 % | $ 34.8 M | USA |
 |
Avenue Therapeutics
ATXI
|
-0.0603 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-0.826 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-0.401 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-0.0633 | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-0.224 | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
-5.11 | $ 12.91 | 1.33 % | $ 778 M | USA |
 |
Atreca
BCEL
|
-0.607 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
7.5 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-1.8 K | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Inventiva S.A.
IVA
|
-11.2 | $ 6.11 | 5.71 % | $ 138 M | France |
 |
Calithera Biosciences
CALA
|
-14.5 | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-0.588 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-0.024 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-4.42 | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
-5.15 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-1.18 | - | -7.23 % | $ 13 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-5.04 | $ 16.73 | -1.59 % | $ 831 M | Britain |
 |
Aeglea BioTherapeutics
AGLE
|
-4.6 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-4.82 | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
-8.74 | $ 21.04 | 4.31 % | $ 3.46 B | USA |
 |
Kamada Ltd.
KMDA
|
-30.7 | $ 8.27 | 0.24 % | $ 260 M | Israel |
 |
Karyopharm Therapeutics
KPTI
|
-0.000574 | $ 6.93 | -9.17 % | $ 845 K | USA |
 |
Keros Therapeutics
KROS
|
4.77 | $ 11.17 | 1.92 % | $ 416 M | USA |
 |
Akero Therapeutics
AKRO
|
-14.1 | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-5.18 | $ 4.3 | 1.37 % | $ 714 M | Canada |
 |
Akouos
AKUS
|
-2.7 | - | 0.23 % | $ 488 M | USA |